Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19181606 | 1.00 | ERBB2 (1.00) | ERBB2 | |
| SCHEMBL31409150 | 1.00 | ERBB2 (1.00) | ERBB2 | |
| SCHEMBL19181634 | 0.94 | ERBB2 (1.00) | ERBB2 | |
| SCHEMBL19181633 | 0.94 | ERBB2 (1.00) | ERBB2 | |
| SCHEMBL19181050 | 0.93 | ERBB2 (1.00) | ERBB2 | |
| SCHEMBL19181051 | 0.93 | ERBB2 (1.00) | ERBB2 | |
| SCHEMBL19182398 | 0.93 | ERBB2 (1.00) | ERBB2 | |
| SCHEMBL19182452 | 0.93 | ERBB2 (1.00) | ERBB2 | |
| SCHEMBL19181661 | 0.93 | ERBB2 (1.00) | ERBB2 | |
| SCHEMBL19182449 | 0.93 | ERBB2 (1.00) | ERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3590516-B1 | ANTITUMOR-EFFECT ENHANCER USING PYRAZOLO[3,4-D]PYRIMIDINE COMPOUND | TAIHO PHARMACEUTICAL CO LTD (JP) | 2025-09-03 | — | — | EP | claimed |
| US-12186320-B2 | Therapeutic agent containing pyrazolo[3,4-d]pyrimidine compound as active ingredient | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2025-01-07 | — | — | US | claimed |
| EP-3845231-B1 | THERAPEUTIC AGENT CONTAINING PYRAZOLO[3,4-D]PYRIMIDINE COMPOUND AS ACTIVE INGREDIENT | TAIHO PHARMACEUTICAL CO LTD (JP) | 2025-01-01 | — | — | EP | claimed |
| US-20210252000-A1 | THERAPEUTIC AGENT CONTAINING PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND AS ACTIVE INGREDIENT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-08-19 | — | — | US | claimed |
| EP-3845231-A1 | THERAPEUTIC AGENT CONTAINING PYRAZOLO[3,4-D]PYRIMIDINE COMPOUND AS ACTIVE INGREDIENT | Taiho Pharmaceutical Co., Ltd. (JP) | 2021-07-07 | — | — | EP | claimed |
| CN-108349981-B | Novel pyrazolo [3, 4-d ] pyrimidine compound or salt thereof | 大鹏药品工业株式会社 | 2021-03-30 | — | — | CN | claimed |
| EP-3345907-B1 | PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS OR SALTS THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2020-04-22 | — | — | EP | claimed |
| US-20200061067-A1 | AGENT ENHANCING ANTITUMOR EFFECT USING PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-02-27 | — | — | US | claimed |
| US-10329300-B2 | Pyrazolo[3,4-d]pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2019-06-25 | — | — | US | claimed |
| US-20180201615-A1 | PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO. , LTD. (JP) | 2018-07-19 | — | — | US | claimed |
| EP-3345907-A1 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2018-07-11 | — | — | EP | claimed |
| US-9920060-B2 | Pyrazolo[3,4-d]pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-03-20 | — | — | US | claimed |
| US-20170217970-A1 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2017-08-03 | — | — | US | claimed |
| EP-3590516-B1 | ANTITUMOR-EFFECT ENHANCER USING PYRAZOLO[3,4-D]PYRIMIDINE COMPOUND | TAIHO PHARMACEUTICAL CO LTD (JP) | 2025-09-03 | — | — | EP | disclosed |
| US-12186320-B2 | Therapeutic agent containing pyrazolo[3,4-d]pyrimidine compound as active ingredient | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2025-01-07 | — | — | US | disclosed |
| EP-3845231-B1 | THERAPEUTIC AGENT CONTAINING PYRAZOLO[3,4-D]PYRIMIDINE COMPOUND AS ACTIVE INGREDIENT | TAIHO PHARMACEUTICAL CO LTD (JP) | 2025-01-01 | — | — | EP | disclosed |
| US-20180201615-A1 | PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO. , LTD. (JP) | 2018-07-19 | — | — | US | disclosed |
| EP-3345907-A1 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2018-07-11 | — | — | EP | disclosed |
| US-9920060-B2 | Pyrazolo[3,4-d]pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-03-20 | — | — | US | disclosed |
| US-20170217970-A1 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210252000-A1 | THERAPEUTIC AGENT CONTAINING PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND AS ACTIVE INGREDIENT | ERBB2, TP53, TK1 | ERBB2 1/4885 |
| US-20170217970-A1 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF | ERBB2, JAK2, ERBB4 | ERBB2 1/4885 |
| US-20180201615-A1 | PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF | ERBB2, JAK2, ERBB4 | ERBB2 1/4885 |
| US-12186320-B2 | Therapeutic agent containing pyrazolo[3,4-d]pyrimidine compound as active ingredient | ERBB2, TP53, TK1 | ERBB2 1/4885 |
| US-10329300-B2 | Pyrazolo[3,4-d]pyrimidine compound or salt thereof | ERBB2, JAK2, ERBB4 | ERBB2 1/4885 |
| US-20200061067-A1 | AGENT ENHANCING ANTITUMOR EFFECT USING PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND | ZYX, DPYD, ZFX | ERBB2 2137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.